Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.

被引：0
|
作者：
Yu, Seo Young [1 ]
Park, Juin [2 ]
Kwon, Woo Sun [2 ]
Jeong, Inhye [2 ]
Kang, Sun Kyoung [2 ]
Bae, Hyun Joo [1 ]
Kim, Tae Soo [2 ]
Chung, Hyun Cheol [3 ]
Rha, Sun Young [3 ]
机构：
[1] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul, South Korea
[2] Yonsei Univ, Songdang Inst Canc Res, Coll Med, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
945
引用
收藏
页数：2
相关论文
共 50 条
  • [41] HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Drago, Joshua Z.
    Pareja, Fresia
    Jhaveri, Komal L.
    Walsh, Elaine M.
    Ku, Geoffrey Yuyat
    Maron, Steven Brad
    Janjigian, Yelena Y.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Modi, Shanu
    Razavi, Pedram
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07): : S31 - S31
  • [43] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S156
  • [44] Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
    Vaz Batista, M.
    Perez-Garcia, J. M.
    Llombart Cussac, A.
    Cortez, P.
    Ruiz Borrego, M.
    De la Haba, J.
    Cejalvo, J. M.
    Racca, F.
    Servitja, S.
    Blanch, S.
    Lema, L.
    Galan Garmaje, M.
    Fernandez-Abad, M.
    Fernandez, A.
    Iranzo, V.
    Gonzalez-Santiago, S.
    Gion, M.
    Nave, M.
    Cortes, J.
    Braga, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S509 - S510
  • [45] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer
    Tsao, Li-Chung
    Wang, John S.
    Ragusa, Joey
    Liu, Bushangqing
    McBane, Jason
    Spasojevic, Ivan
    Fan, Ping
    Trotter, Timothy N.
    Lyerly, Herbert Kim
    Hartman, Zachary C.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [47] Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies
    Li, Claire
    Henning, Stefanie
    Patel, Kashyap
    Hui, Katrina
    van der Vleuten, Gerly
    Abutarif, Malaz
    Garimella, Tushar
    Khatri, Amit
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Trastuzumab-deruxtecan in HER2 positive advanced gastric or gastroesophageal junction cancer after previous treatment with trastuzumab
    Duval, Jeanne
    Zaanan, Aziz
    BULLETIN DU CANCER, 2023, 110 (7-8) : 739 - 740
  • [49] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [50] Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)
    Hingorani, Pooja
    Zhang, Wendong
    Kurmasheva, Raushan
    Zhang, Zhongting
    Wang, Yifei
    Xu, Zhaohui
    Roth, Michael
    Gill, Jonathan
    Harrison, Douglas
    Erickson, Stephen
    Kolb, Edward A.
    Smith, Malcolm
    Houghton, Peter
    Gorlick, Richard
    CANCER RESEARCH, 2020, 80 (16)
12345